慢性肝病合并自身免疫性血液系统疾病的临床特征及应用糖皮质激素治疗效果分析  

Clinical features of chronic liver disease with autoimmune blood diseases and the clinical effect of glucocorticoid

作　　者：刘龙[1] 刘遥[1] 高方媛[1] 王宪波[1] LIU Long;LIU Yao;GAO Fangyuan;WANG Xianbo(Department of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)

机构地区：[1]首都医科大学附属北京地坛医院中西医结合中心,北京100015

出　　处：《临床肝胆病杂志》2021年第8期1878-1882,共5页Journal of Clinical Hepatology

基　　金：首都卫生发展科研专项项目(2018-1-2172);北京市科学技术委员会资助(Z191100006619033)。

摘　　要：目的分析慢性肝病合并免疫性血液系统疾病的临床特征,探究糖皮质激素的疗效。方法回顾性分析2008年1月-2019年12月北京地坛医院收治的17例慢性肝病合并免疫性血液病患者的临床资料,根据血液病种类分为3组:自身免疫性溶血性贫血(AIHA)组、免疫性血小板减少症(ITP)组、Evans综合征组。进行糖皮质激素治疗及肝病相关治疗后,比较3组治疗前后临床资料及实验室检查指标。计量资料两组间比较采用Mann-Whitney U检验。结果 17例慢性肝病患者中有15例非病毒性肝炎患者,其中自身免疫性肝病9例(占52.9%)。17例患者血液系统疾病分布:AIHA患者6例,ITP患者8例,Evans综合征患者3例。其中13例患者进行糖皮质激素治疗,达到完全缓解或部分缓解者共12例,总有效率92.3%。ITP组TBil、DBil治疗后较治疗前显著下降[35.8(14.3~58.0)μmol/L vs 165.6(21.3~374.3)μmol/L,Z=-2.205,P=0.027;24.9(7.0~43.3)μmol/L vs 121.9(11.7~279.9)μmol/L,Z=-2.205,P=0.027];AIHA组血红蛋白治疗后较治疗前显著上升[94.0(65.0~993)g/L vs 62.2(42.3~80.5)g/L,Z=-2.242,P=0.025]。结论多种类型慢性肝病均可合并免疫性血液系统疾病,其中自身免疫性肝病合并免疫性血液系统疾病的发病率较高;糖皮质激素是慢性肝病合并免疫性血液系统疾病安全有效的治疗方法。Objective To investigate the clinical features of chronic liver disease with immune blood diseases and the clinical effect of glucocorticoid therapy.Methods A retrospective analysis was performed for the clinical data of 17 patients with chronic liver disease and immune blood diseases who were admitted to Beijing Ditan Hospital from January 2008 to December 2019,and according to the type of blood disease,they were divided into autoimmune hemolytic anemia(AIHA)group,immune thrombocytopenia(ITP)group,and Evans syndrome group.After glucocorticoid therapy and related treatment of liver disease,the three groups were compared in terms of clinical data and laboratory markers before and after treatment.The Mann-Whitney U test was used for comparison of continuous data between two groups.Results Among the 17 patients with chronic liver disease,15 had no viral hepatitis,among whom 9(52.9%)had autoimmune liver disease.Among these 17 patients,6 had AIHA,8 had ITP,and 3 had Evans syndrome.Glucocorticoid therapy was given for 13 patients,among whom12 achieved complete remission or partial remission,resulting in an overall response rate of 92.3%.After treatment,the ITP group had significant reductions in total bilirubin[35.8(14.3-58.0)μmol/L vs 165.6(21.3-374.3)μmol/L,Z=-2.205,P=0.027]and direct bilirubin[24.9(7.0-43.3)μmol/L vs 121.9(11.7-279.9)μmol/L,Z=-2.205,P=0.027],and the AIHA group had a significant increase in hemoglobin[94.0(65.0-99.3)g/L vs 62.2(42.3-80.5)g/L,Z=-2.242,P=0.025].Conclusion Immune blood diseases are observed in patients with various types of chronic liver disease,among which autoimmune liver disease with immune blood diseases has a relatively high incidence rate.Glucocorticoid is a safe and effective therapeutic method for the treatment of chronic liver disease with immune blood diseases.

关 键 词：肝疾病 贫血 溶血性 自身免疫性 紫癜 血小板减少性 特发性 EVANS综合征 糖皮质激素类 

分 类 号：R575[医药卫生—消化系统]